<DOC>
	<DOCNO>NCT02279134</DOCNO>
	<brief_summary>This phase III trial study well combination chemoradiation radiation work resect locally advanced cancer esophagus gastroesophageal junction .</brief_summary>
	<brief_title>Phase II/III Study Compare Adjuvant Chemoradiotherapy , Radiotherapy Surgery Alone Esophageal Carcinoma</brief_title>
	<detailed_description>Although preoperative chemoradiation therapy follow surgery common approach patient resectable esophageal cancer , considerable number esophageal cancer patient receive operation first treatment modality . Accordingly , postoperative treatment always play important role poor survival rate patient stage ⅡB [ UICC 7th edition ] -Ⅲ [ UICC 7th edition ] treat resection alone . The exist data show 5-yeal survival rate stageⅡB-Ⅲ thoracic esophageal squamous cell carcinoma ( TESCC ) surgery merely 28.4 % , locoregional lymph node metastases responsible main cause failure . While proved value prophylactic radiation therapy radical esophagectomy esophageal carcinoma positive lymph node metastases stage Ⅲ disease ( UICC 6th edition ) conventional 2-dimensional radiotherapy method subset analysis prospective randomize clinical trial . For patient positive lymph node , 5 year survival surgery alone 28.4 % , median overall survival 24 month , recurrence pattern 34.6 % mediastinal lymph nodes，13.3 % supraclavicular lymph nodes，10 % abdominal lymph node . Distant metastasis occur 21 % patient . Adjuvant radiotherapy significantly reduce recurrence mediastinal lymph node ( 13.4 % ) , supraclavicular lymph node ( 6.1 % ) . However distant metastasis rate increase 30.7 % . Chemotherapy may vital patient . Chen report 5 year overall survival rate chemoradiotherapy group radiotherapy group 47.4 % 38.6 % ( P=0.03 ) . Based study , treatment failure occur 8 % patient celiac metastasis . Small radiation field omit celiac drainage region may ensure patient accept 2 cycle concurrent chemotherapy low toxicity .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . KPS≥70 2 . Diagnosis stage ⅡB Ⅲ thoracic esophageal cancer 3 . Complete resection 4 . Adequate organ function : Hematopoietic Absolute granulocyte count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hemoglobin least 10 g/dL Hepatic Not specify Renal Creatinine great 1.5 mg/dL AND/OR Creatinine clearance least 65 mL/min Calcium great 11 mg/dL Cardiovascular No uncontrolled heart disease No uncontrolled hypertension 1 . Uncontrolled diabetes 2 . Interval surgery adjuvant therapy 3 month 3 . Sign recurrence CT scan ultrasound PETCT No palpable subclavicular lymph node involvement cytology needle aspiration No lymph node great 1 cm CT scan 4 . With Weight loss great 10 % baseline 5 . With prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix 6 . Be pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>StageⅡB-Ⅲ esophageal cancer</keyword>
	<keyword>adjuvant radiotherapy</keyword>
	<keyword>adjuvant chemoradiotherapy</keyword>
</DOC>